Published in Nat Rev Cancer on January 19, 2012
The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer (2013) 4.20
C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma. Nature (2014) 2.44
Epigenetic regulation of SOX9 by the NF-κB signaling pathway in pancreatic cancer stem cells. Stem Cells (2013) 2.40
Metabolic targets for cancer therapy. Nat Rev Drug Discov (2013) 2.32
Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med (2013) 2.20
The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat Rev Drug Discov (2013) 1.93
Genetic variation in innate immunity and inflammation pathways associated with lung cancer risk. Cancer (2012) 1.58
Telomerase directly regulates NF-κB-dependent transcription. Nat Cell Biol (2012) 1.53
Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA. Oncogene (2013) 1.44
Anti-tumour strategies aiming to target tumour-associated macrophages. Immunology (2013) 1.40
Specific recognition of linear polyubiquitin by A20 zinc finger 7 is involved in NF-κB regulation. EMBO J (2012) 1.39
TGF-β and NF-κB signal pathway cross-talk is mediated through TAK1 and SMAD7 in a subset of head and neck cancers. Oncogene (2012) 1.26
Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. Cancer Res (2013) 1.26
STAT3 and epithelial-mesenchymal transitions in carcinomas. JAKSTAT (2014) 1.24
Non-canonical NF-κB signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activation. Nat Cell Biol (2015) 1.18
O-GlcNAcylation: A New Cancer Hallmark? Front Endocrinol (Lausanne) (2013) 1.16
p-21 activated kinase 4 promotes proliferation and survival of pancreatic cancer cells through AKT- and ERK-dependent activation of NF-κB pathway. Oncotarget (2014) 1.15
MicroRNA-26b suppresses the NF-κB signaling and enhances the chemosensitivity of hepatocellular carcinoma cells by targeting TAK1 and TAB3. Mol Cancer (2014) 1.14
GSK-3α promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of noncanonical NF-κB. Cancer Discov (2013) 1.13
NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer. Cell Rep (2015) 1.13
PIWI Expression and Function in Cancer. Front Genet (2012) 1.12
Cancer metabolism and elevated O-GlcNAc in oncogenic signaling. J Biol Chem (2014) 1.11
NF-κB-induced KIAA1199 promotes survival through EGFR signalling. Nat Commun (2014) 1.09
Aberrant regulation of FBW7 in cancer. Oncotarget (2014) 1.08
Proteomic screen reveals Fbw7 as a modulator of the NF-κB pathway. Nat Commun (2012) 1.07
ROS-induced epithelial-mesenchymal transition in mammary epithelial cells is mediated by NF-kB-dependent activation of Snail. Oncotarget (2014) 1.07
The NF-κB RelB protein is an oncogenic driver of mesenchymal glioma. PLoS One (2013) 1.04
Co-inhibition of NF-κB and JNK is synergistic in TNF-expressing human AML. J Exp Med (2014) 1.03
Signaling cross-talk in the resistance to HER family receptor targeted therapy. Oncogene (2013) 1.03
Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy. Nature (2014) 1.03
Histone methyltransferase NSD2/MMSET mediates constitutive NF-κB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop. Mol Cell Biol (2012) 1.02
NEMO Prevents Steatohepatitis and Hepatocellular Carcinoma by Inhibiting RIPK1 Kinase Activity-Mediated Hepatocyte Apoptosis. Cancer Cell (2015) 1.02
Small-molecule SMAC mimetics as new cancer therapeutics. Pharmacol Ther (2014) 0.99
PSGR promotes prostatic intraepithelial neoplasia and prostate cancer xenograft growth through NF-κB. Oncogenesis (2014) 0.98
Identification of DR5 as a critical, NF-κB-regulated mediator of Smac-induced apoptosis. Cell Death Dis (2013) 0.98
SAMNet: a network-based approach to integrate multi-dimensional high throughput datasets. Integr Biol (Camb) (2012) 0.98
Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB. PLoS One (2015) 0.97
DEAD-box helicase DP103 defines metastatic potential of human breast cancers. J Clin Invest (2014) 0.97
Identification and functional characterization of FMN2, a regulator of the cyclin-dependent kinase inhibitor p21. Mol Cell (2013) 0.97
Regulation of p53 and Rb links the alternative NF-κB pathway to EZH2 expression and cell senescence. PLoS Genet (2014) 0.97
Rho protein GTPases and their interactions with NFκB: crossroads of inflammation and matrix biology. Biosci Rep (2014) 0.96
An evolving role for DEPTOR in tumor development and progression. Neoplasia (2012) 0.96
Anti-oxidative stress response genes: bioinformatic analysis of their expression and relevance in multiple cancers. Oncotarget (2013) 0.94
Akt-dependent activation of mTORC1 complex involves phosphorylation of mTOR (mammalian target of rapamycin) by IκB kinase α (IKKα). J Biol Chem (2014) 0.94
Cyclin-dependent kinase 6 phosphorylates NF-κB P65 at serine 536 and contributes to the regulation of inflammatory gene expression. PLoS One (2012) 0.93
Emerging roles of PDGF-D in EMT progression during tumorigenesis. Cancer Treat Rev (2012) 0.93
A systematic screen reveals MicroRNA clusters that significantly regulate four major signaling pathways. PLoS One (2012) 0.92
30 Years of NF-κB: A Blossoming of Relevance to Human Pathobiology. Cell (2017) 0.92
Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism. J Inflamm (Lond) (2014) 0.92
Acidosis promotes invasiveness of breast cancer cells through ROS-AKT-NF-κB pathway. Oncotarget (2014) 0.92
In vivo circadian oscillation of dCREB2 and NF-κB activity in the Drosophila nervous system. PLoS One (2012) 0.91
NF-κB and STAT3 in glioblastoma: therapeutic targets coming of age. Expert Rev Neurother (2014) 0.91
The interaction between ER and NFκB in resistance to endocrine therapy. Breast Cancer Res (2012) 0.90
Activation of the NF-κB pathway by the STAT3 inhibitor JSI-124 in human glioblastoma cells. Mol Cancer Res (2013) 0.90
The coactivator role of histone deacetylase 3 in IL-1-signaling involves deacetylation of p65 NF-κB. Nucleic Acids Res (2012) 0.90
Nuclear factor-ĸB plays a critical role in both intrinsic and acquired resistance against endocrine therapy in human breast cancer cells. Sci Rep (2014) 0.90
The pharmacological NF-κB inhibitor BAY11-7082 induces cell apoptosis and inhibits the migration of human uveal melanoma cells. Int J Mol Sci (2012) 0.89
The role of hypoxia in inflammatory disease (review). Int J Mol Med (2015) 0.89
Computational Modelling of NF-κB Activation by IL-1RI and Its Co-Receptor TILRR, Predicts a Role for Cytoskeletal Sequestration of IκBα in Inflammatory Signalling. PLoS One (2015) 0.88
Proteasome inhibitors block DNA repair and radiosensitize non-small cell lung cancer. PLoS One (2013) 0.88
NF-κB is a critical mediator of BRCA1-induced chemoresistance. Oncogene (2013) 0.88
Concordance of gene expression in human protein complexes reveals tissue specificity and pathology. Nucleic Acids Res (2013) 0.87
The canonical NF-κB pathway differentially protects normal and human tumor cells from ROS-induced DNA damage. Cell Signal (2012) 0.87
Directly targeting transcriptional dysregulation in cancer. Nat Rev Cancer (2015) 0.87
Frequent engagement of RelB activation is critical for cell survival in multiple myeloma. PLoS One (2013) 0.87
MicroRNA and signal transduction pathways in tumor radiation response. Cell Signal (2013) 0.87
Reactivation of telomerase in cancer. Cell Mol Life Sci (2016) 0.87
Bromodomain and extraterminal (BET) protein inhibition suppresses human T cell leukemia virus 1 (HTLV-1) Tax protein-mediated tumorigenesis by inhibiting nuclear factor κB (NF-κB) signaling. J Biol Chem (2013) 0.87
Inhibition of RelA-Ser536 phosphorylation by a competing peptide reduces mouse liver fibrosis without blocking the innate immune response. Hepatology (2013) 0.86
IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel. Nat Commun (2015) 0.86
EGF receptor uses SOS1 to drive constitutive activation of NFκB in cancer cells. Proc Natl Acad Sci U S A (2014) 0.86
Temporal regulation of HIF-1 and NF-κB in hypoxic hepatocarcinoma cells. Oncotarget (2015) 0.86
Hepatocellular alterations and dysregulation of oncogenic pathways in the liver of transgenic mice overexpressing growth hormone. Cell Cycle (2013) 0.85
RelA regulates CXCL1/CXCR2-dependent oncogene-induced senescence in murine Kras-driven pancreatic carcinogenesis. J Clin Invest (2016) 0.85
RNF20 Links Histone H2B Ubiquitylation with Inflammation and Inflammation-Associated Cancer. Cell Rep (2016) 0.85
Negative regulation of NF-κB signaling in T lymphocytes by the ubiquitin-specific protease USP34. Cell Commun Signal (2013) 0.85
Cyclosporin A inhibits colon cancer cell growth independently of the calcineurin pathway. Cell Cycle (2012) 0.84
TNFα sensitizes neuroblastoma cells to FasL-, cisplatin- and etoposide-induced cell death by NF-κB-mediated expression of Fas. Mol Cancer (2015) 0.84
Distinct phenotypes of human prostate cancer cells associate with different adaptation to hypoxia and pro-inflammatory gene expression. PLoS One (2014) 0.84
cIAP2 represses IKKα/β-mediated activation of MDM2 to prevent p53 degradation. Cell Cycle (2012) 0.84
Aryl hydrocarbon receptor nuclear translocator (ARNT) isoforms control lymphoid cancer cell proliferation through differentially regulating tumor suppressor p53 activity. Oncotarget (2016) 0.84
TfR1 interacts with the IKK complex and is involved in IKK-NF-κB signalling. Biochem J (2013) 0.83
Anti-metastatic and anti-tumor growth effects of Origanum majorana on highly metastatic human breast cancer cells: inhibition of NFκB signaling and reduction of nitric oxide production. PLoS One (2013) 0.83
YM155 potently triggers cell death in breast cancer cells through an autophagy-NF-kB network. Oncotarget (2015) 0.83
Genome-wide analysis reveals a role for BRCA1 and PALB2 in transcriptional co-activation. EMBO J (2014) 0.83
The diverse and complex roles of radiation on cancer treatment: therapeutic target and genome maintenance. Am J Cancer Res (2012) 0.83
A curated census of autophagy-modulating proteins and small molecules: candidate targets for cancer therapy. Autophagy (2014) 0.82
Inhibition of mitogen activated protein kinases increases the sensitivity of A549 lung cancer cells to the cytotoxicity induced by a kava chalcone analog. Biochem Biophys Res Commun (2012) 0.82
Telomerase reverse transcriptase in the regulation of gene expression. BMB Rep (2014) 0.82
c-Rel is a critical mediator of NF-κB-dependent TRAIL resistance of pancreatic cancer cells. Cell Death Dis (2014) 0.82
Regulation of cancer metabolism by O-GlcNAcylation. Glycoconj J (2013) 0.82
Regulation of TAK1/TAB1-mediated IL-1β signaling by cytoplasmic PPARβ/δ. PLoS One (2013) 0.82
Regulation of signal transduction by glutathione transferases. Int J Hepatol (2012) 0.82
NF-κB and HIF crosstalk in immune responses. FEBS J (2015) 0.82
Impaired mitochondrial metabolism and mammary carcinogenesis. J Mammary Gland Biol Neoplasia (2012) 0.82
Involvement of RNA Polymerase III in Immune Responses. Mol Cell Biol (2015) 0.82
Intracellular annexin A2 regulates NF-κB signaling by binding to the p50 subunit: implications for gemcitabine resistance in pancreatic cancer. Cell Death Dis (2015) 0.81
Reactivation of epigenetically silenced miR-512 and miR-373 sensitizes lung cancer cells to cisplatin and restricts tumor growth. Cell Death Differ (2015) 0.81
Parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-Mhigh melanoma cell populations. Oncotarget (2016) 0.81
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
Immunity, inflammation, and cancer. Cell (2010) 28.27
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res (2010) 25.55
Shared principles in NF-kappaB signaling. Cell (2008) 20.96
Nuclear factor-kappaB in cancer development and progression. Nature (2006) 18.31
The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet (2008) 16.09
IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell (2004) 15.82
NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature (2004) 15.14
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene (1999) 13.46
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature (2011) 11.44
Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature (1995) 10.36
Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol (2007) 10.23
An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell (2009) 10.09
Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov (2009) 6.36
The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov (2004) 6.21
Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol (2011) 6.17
SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organismal life span. Cell (2009) 6.09
Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell (2007) 5.91
Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med (1997) 5.72
Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature (2009) 4.93
Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway. Oncogene (2006) 4.62
Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature (2011) 4.57
NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell (2007) 4.56
IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature (2005) 4.31
Pulsatile stimulation determines timing and specificity of NF-kappaB-dependent transcription. Science (2009) 4.14
Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev (2009) 4.10
Nuclear factor-kappaB: its role in health and disease. J Mol Med (Berl) (2004) 4.01
Genetic analysis of NF-kappaB/Rel transcription factors defines functional specificities. EMBO J (2003) 3.93
NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol (2009) 3.86
Regulation of tissue homeostasis by NF-kappaB signalling: implications for inflammatory diseases. Nat Rev Immunol (2009) 3.51
Mutations in the NF-kappaB signaling pathway: implications for human disease. Oncogene (2006) 3.49
Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol (2009) 3.47
Active repression of antiapoptotic gene expression by RelA(p65) NF-kappa B. Mol Cell (2004) 3.45
Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB. Mol Cell (2007) 3.42
Transcriptional cross talk between NF-kappaB and p53. Mol Cell Biol (1999) 3.40
Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol (2010) 3.30
TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. Cancer Cell (2010) 3.25
B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature (2010) 3.24
Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappaB. Mol Cell Biol (2000) 3.23
Control of the senescence-associated secretory phenotype by NF-κB promotes senescence and enhances chemosensitivity. Genes Dev (2011) 3.05
Good cop, bad cop: the different faces of NF-kappaB. Cell Death Differ (2006) 3.04
Essential cytoplasmic translocation of a cytokine receptor-assembled signaling complex. Science (2008) 2.99
Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. Genes Dev (2008) 2.89
Cell surface-bound IL-1alpha is an upstream regulator of the senescence-associated IL-6/IL-8 cytokine network. Proc Natl Acad Sci U S A (2009) 2.82
p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat Cell Biol (2008) 2.81
Jmjd3 contributes to the control of gene expression in LPS-activated macrophages. EMBO J (2009) 2.72
NF-kappaB and IKK as therapeutic targets in cancer. Cell Death Differ (2006) 2.59
A nuclear poly(ADP-ribose)-dependent signalosome confers DNA damage-induced IkappaB kinase activation. Mol Cell (2009) 2.56
Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev (2009) 2.35
Inhibitors of NF-kappaB signaling: 785 and counting. Oncogene (2006) 2.33
p53 stabilization is decreased upon NFkappaB activation: a role for NFkappaB in acquisition of resistance to chemotherapy. Cancer Cell (2002) 2.31
Phosphorylation of serine 468 by GSK-3beta negatively regulates basal p65 NF-kappaB activity. J Biol Chem (2004) 2.29
CK2 Is a C-Terminal IkappaB Kinase Responsible for NF-kappaB Activation during the UV Response. Mol Cell (2003) 2.23
Signaling to NF-kappaB: regulation by ubiquitination. Cold Spring Harb Perspect Biol (2010) 2.15
IKK/NF-kappaB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis. EMBO Rep (2009) 2.14
Context-specific regulation of NF-κB target gene expression by EZH2 in breast cancers. Mol Cell (2011) 2.12
p53 induces NF-kappaB activation by an IkappaB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1. J Biol Chem (2004) 2.01
Deubiquitinases in the regulation of NF-κB signaling. Cell Res (2010) 2.00
Posttranslational modifications of NF-kappaB: another layer of regulation for NF-kappaB signaling pathway. Cell Signal (2010) 1.99
A novel nuclear factor-kappaB gene signature is differentially expressed in head and neck squamous cell carcinomas in association with TP53 status. Clin Cancer Res (2007) 1.96
Classical and/or alternative NF-kappaB pathway activation in multiple myeloma. Blood (2010) 1.96
p53- and Mdm2-independent repression of NF-kappa B transactivation by the ARF tumor suppressor. Mol Cell (2003) 1.92
Lipopolysaccharide activation of the TPL-2/MEK/extracellular signal-regulated kinase mitogen-activated protein kinase cascade is regulated by IkappaB kinase-induced proteolysis of NF-kappaB1 p105. Mol Cell Biol (2004) 1.86
Angiotensin II activates I kappaB kinase phosphorylation of RelA at Ser 536 to promote myofibroblast survival and liver fibrosis. Gastroenterology (2009) 1.84
The NF-kappaB-independent functions of IKK subunits in immunity and cancer. Trends Cell Biol (2009) 1.81
SUMOylation-dependent localization of IKKepsilon in PML nuclear bodies is essential for protection against DNA-damage-triggered cell death. Mol Cell (2010) 1.79
The anti-apoptotic activities of Rel and RelA required during B-cell maturation involve the regulation of Bcl-2 expression. EMBO J (2000) 1.79
NF-κB controls energy homeostasis and metabolic adaptation by upregulating mitochondrial respiration. Nat Cell Biol (2011) 1.77
p53 and NF-κB: different strategies for responding to stress lead to a functional antagonism. FASEB J (2010) 1.77
The nuclear signaling of NF-kappaB: current knowledge, new insights, and future perspectives. Cell Res (2009) 1.77
IkappaB kinase is an essential component of the Tpl2 signaling pathway. Mol Cell Biol (2004) 1.76
p53 represses cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-kappaB subunit with histone deacetylase 1. Mol Cell Biol (2003) 1.75
Mechanism of hypoxia-induced NF-kappaB. Mol Cell Biol (2010) 1.74
Regulation of p53 tumour suppressor target gene expression by the p52 NF-kappaB subunit. EMBO J (2006) 1.73
Opposing roles of NF-κB in anti-cancer treatment outcome unveiled by cross-species investigations. Genes Dev (2011) 1.69
Regulation of NF-kappaB and p53 through activation of ATR and Chk1 by the ARF tumour suppressor. EMBO J (2005) 1.69
IkappaBbeta acts to inhibit and activate gene expression during the inflammatory response. Nature (2010) 1.68
p53-mediated induction of Noxa and p53AIP1 requires NFkappaB. Cell Cycle (2010) 1.67
Population robustness arising from cellular heterogeneity. Proc Natl Acad Sci U S A (2010) 1.66
Repression of gene expression by unphosphorylated NF-kappaB p65 through epigenetic mechanisms. Genes Dev (2008) 1.64
Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. Cancer Res (2007) 1.64
ATM- and NEMO-dependent ELKS ubiquitination coordinates TAK1-mediated IKK activation in response to genotoxic stress. Mol Cell (2010) 1.64
GCN5 is a required cofactor for a ubiquitin ligase that targets NF-kappaB/RelA. Genes Dev (2009) 1.62
Many faces of NF-kappaB signaling induced by genotoxic stress. J Mol Med (Berl) (2007) 1.61
Retracted A cell cycle regulatory network controlling NF-kappaB subunit activity and function. EMBO J (2007) 1.58
IKK-i/IKKepsilon controls constitutive, cancer cell-associated NF-kappaB activity via regulation of Ser-536 p65/RelA phosphorylation. J Biol Chem (2006) 1.57
The putative oncoprotein Bcl-3 induces cyclin D1 to stimulate G(1) transition. Mol Cell Biol (2001) 1.55
Phosphorylation of NF-kappaB p65 at Ser468 controls its COMMD1-dependent ubiquitination and target gene-specific proteasomal elimination. EMBO Rep (2009) 1.54
p53-mediated repression of nuclear factor-kappaB RelA via the transcriptional integrator p300. Cancer Res (1998) 1.51
Telomere-independent Rap1 is an IKK adaptor and regulates NF-kappaB-dependent gene expression. Nat Cell Biol (2010) 1.47
CREB-binding protein is a nuclear integrator of nuclear factor-kappaB and p53 signaling. J Biol Chem (1999) 1.47
LZAP, a putative tumor suppressor, selectively inhibits NF-kappaB. Cancer Cell (2007) 1.47
Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1. Mol Cell Biol (2005) 1.46
Induction of a pro-apoptotic ATM-NF-kappaB pathway and its repression by ATR in response to replication stress. EMBO J (2008) 1.46
cis-acting, element-specific transcriptional activity of differentially phosphorylated nuclear factor-kappa B. J Biol Chem (2004) 1.44
Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel. Oncogene (1999) 1.41
NF-kappa B activation mediates doxorubicin-induced cell death in N-type neuroblastoma cells. J Biol Chem (2001) 1.39
Cross talk between stimulated NF-kappaB and the tumor suppressor p53. Oncogene (2010) 1.38
Cysteine 38 holds the key to NF-κB activation. Mol Cell (2012) 0.81